Carisma Therapeutics (CARM) Company Overview

Resources realigned to focus primarily on in vivo macrophage engineering platform for fibrosis, oncology and autoimmune disease therapies Development of CT-0525 to be discontinued; workforce reduced by 34% PHILADELPHIA , Dec. 9, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM ) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced a strategic reprioritization of its pipeline, cessation of development of CT-0525, and a reduction in the workforce by 34%. These measures will enable Carisma to focus its resources on advancing its in vivo macrophage engineering platform for the development of fibrosis, oncology and autoimmune disease therapies.

New preclinical results support the anti-fibrotic potential of engineered macrophages in multiple fibrosis models Engineered TIM4-expressing macrophages correct defective efferocytosis in MASH, demonstrating potent anti-fibrotic activity  PHILADELPHIA , Nov. 17, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today presented promising preclinical data on engineered macrophages for treating liver fibrosis at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024. These results underscore the pre-clinical efficacy of Carisma's engineered macrophages in multiple liver fibrosis models and offer a novel, off-the-shelf potential treatment option for patients with fibrotic liver disease including advanced metabolic dysfunction-associated steatohepatitis (MASH).

Appointment of Sohanya Cheng Resignation of Michael Torok PHILADELPHIA , Oct. 30, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Sohanya Cheng, MBA to the Company's Board of Directors, effective October 31, 2024. Additionally, Michael Torok has informed the Board of his intention to step down as a member, effective October 31, 2024, due to other professional commitments.

PHILADELPHIA , Sept. 3, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in the following upcoming conferences: Baird 2024 Global Healthcare Conference Tuesday, September 10 at 12:50 PM ET New York, NY H.C.

CARISMA THERAP (CARM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Initial data for CT-0525, lead product candidate for anti-HER2 program, expected by year-end 2024 Nomination of a development candidate for liver fibrosis program expected in the first quarter of 2025 Nominated first in vivo CAR-M development candidate targeting Glypican-3 to treat hepatocellular carcinoma under the Moderna Collaboration in the second quarter of 2024 Cash and cash equivalents of $40.4 million and $2.0 million received in July under the Moderna Collaboration expected to fund the Company into the third quarter of 2025 PHILADELPHIA , Aug. 8, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the quarter ended June 30, 2024, and highlighted recent business updates. "We've achieved considerable clinical and research advancements this year, and I'm excited about our strong momentum and clear focus for the next 12 months," said Steven Kelly, President and Chief Executive Officer of Carisma.

PHILADELPHIA , Aug. 6, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming poster presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024, taking place in San Diego, California, November 15 – 19, 2024. Details on the poster presentation at AASLD 2024 are below: Title: Engineered Macrophages Expressing Fibrosis-Modifying Transgenes Ameliorate Liver Fibrosis in Preclinical Models Session Title: MASLD/MASH - Therapeutics: New Agents Publication Number: 3214 Session Date & Time: 11/17/2024, 8:00 am - 5:00 pm The poster presented at AASLD 2024 will be available online in the "Publications" section of Carisma's website at https://carismatx.com/technology/publications/ following the start of the poster session.

Appointment of David Scadden, M.D. and Marella Thorell Resignation of Regina Hodits and Björn Odlander PHILADELPHIA , July 1, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Marella Thorell and David Scadden, M.D.

Meeting will be reconvened on Friday, June 14, 2024 at 10:00 a.m. Eastern Time  PHILADELPHIA , June 13, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company's virtual annual meeting of stockholders held on June 13, 2024 was convened and adjourned, without any business being conducted, due to technical difficulties with the third-party hosting site.